ATE321885T1 - Modulation der neurokrinen differenzierung durch protein 25.1 - Google Patents

Modulation der neurokrinen differenzierung durch protein 25.1

Info

Publication number
ATE321885T1
ATE321885T1 AT00975512T AT00975512T ATE321885T1 AT E321885 T1 ATE321885 T1 AT E321885T1 AT 00975512 T AT00975512 T AT 00975512T AT 00975512 T AT00975512 T AT 00975512T AT E321885 T1 ATE321885 T1 AT E321885T1
Authority
AT
Austria
Prior art keywords
differentiation
neurocrine
modulation
protein
cancer
Prior art date
Application number
AT00975512T
Other languages
English (en)
Inventor
Elizabeth Wilson
Ron G Rosenfeld
Youngman Oh
Original Assignee
Univ Oregon Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences filed Critical Univ Oregon Health Sciences
Application granted granted Critical
Publication of ATE321885T1 publication Critical patent/ATE321885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
AT00975512T 1999-10-29 2000-10-30 Modulation der neurokrinen differenzierung durch protein 25.1 ATE321885T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16239399P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
ATE321885T1 true ATE321885T1 (de) 2006-04-15

Family

ID=22585428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00975512T ATE321885T1 (de) 1999-10-29 2000-10-30 Modulation der neurokrinen differenzierung durch protein 25.1

Country Status (6)

Country Link
EP (1) EP1226279B1 (de)
JP (1) JP2003513641A (de)
AT (1) ATE321885T1 (de)
CA (1) CA2389575A1 (de)
DE (1) DE60027042D1 (de)
WO (1) WO2001032925A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
WO2017121832A1 (en) * 2016-01-14 2017-07-20 European Molecular Biology Laboratory Microfluidic analysis of ligand induced cell expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules

Also Published As

Publication number Publication date
WO2001032925A9 (en) 2002-08-08
JP2003513641A (ja) 2003-04-15
CA2389575A1 (en) 2001-05-10
EP1226279A4 (de) 2003-06-04
DE60027042D1 (de) 2006-05-18
WO2001032925A1 (en) 2001-05-10
EP1226279A1 (de) 2002-07-31
EP1226279B1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
Spenlé et al. Tenascin-C: Exploitation and collateral damage in cancer management
ATE427354T1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
CA2438143A1 (en) Modified proteins, designer toxins, and methods of making thereof
EP1137658A4 (de) VERFAHREN ZUR MODULATION VON TUMOR NECROSIS FAKTOR -g(a)-INDUZIERTER EXPRESSION VON ZELLADHÄSIONSMOLEKÜLEN
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
AU9021898A (en) Prostate tumor polynucleotide and antigen compositions
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
EP0815202A4 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DK1149111T3 (da) Fremgangsmåde og sammensætning til inhibering af angiogenese
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
DE69935220D1 (de) Von menschlichem tumor stammendes polypeptidhormon phosphatonin
MXPA02008239A (es) Gen humano de la esquizofrenia.
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
EP1226279A4 (de) Modulation der neurokrinen differenzierung durch protein 25.1
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
CA2294514A1 (en) Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties